You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Bio-Techne expects the acquisition will provide it with a basis to build out its IVD presence, given Asuragen's diagnostic tests and regulatory expertise.
Bio-Techne said Asuragen's headquarters in Austin, Texas includes a scalable 50,000-square-foot manufacturing facility and CLIA-certified laboratory.
The test can help diagnose spinal muscular atrophy and identify carriers without symptoms who may be at risk of passing the disease to their children.
Abbott received five separate clearances associated with its i-Stat Chem8+ cartridge running on the company's iStat 1 system.
The firm's AmplideX Fragile X Dx and Carrier Screen Kit is intended to help diagnose fragile X syndrome and assess parental risk of having a child with the syndrome.
Asuragen will use its Amplidex PCR tech to develop companion diagnostics for Wave's investigational allele-selective therapeutic programs for Huntington's.
The disease is an inherited form of muscular dystrophy characterized by a repeat expansion of 50 CTG trinucleotides or greater in the DMPK gene.
The tests from Asuragen and MolecularMD are designed for use in chronic myeloid leukemia patients, including those receiving tyrosine kinase inhibitor therapy.
Asuragen's technology will be used in the Early Check study to identify children with rare health conditions, such as fragile X syndrome, before symptoms appear.
Asuragen test kits to detect major and minor BCR-ABL fusions can now run on the Roche Diagnostics Cobas z 480 Analyzer.